Covered recipient · General Payments record
KEVIN D CANNON
Allopathic & Osteopathic Physicians Hospitalist
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$1,400.30
14 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $734.46 | 10 |
| Travel and Lodging | $633.57 | 3 |
| Education | $32.27 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim International GmbH | $1,243.57 | 12 |
| Corcept Therapeutics | $124.46 | 1 |
| Novo Nordisk Inc | $32.27 | 1 |
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KEVIN D CANNON
NPI 1700897022 · CMS profile ID 122867
Allopathic & Osteopathic Physicians / Hospitalist
WILMINGTON, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1700897022?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
14 matching records · $1,400.30 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–14 of 14.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics | $124.46 | 11/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050843777 | CMS |
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331829 | CMS |
| Boehringer Ingelheim International GmbH | $117.11 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331831 | CMS |
| Boehringer Ingelheim International GmbH | $145.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331833 | CMS |
| Boehringer Ingelheim International GmbH | $145.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331835 | CMS |
| Boehringer Ingelheim International GmbH | $258.23 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331837 | CMS |
| Boehringer Ingelheim International GmbH | $40.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331839 | CMS |
| Boehringer Ingelheim International GmbH | $40.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331841 | CMS |
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331843 | CMS |
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331847 | CMS |
| Boehringer Ingelheim International GmbH | $40.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017331849 | CMS |
| Boehringer Ingelheim International GmbH | $258.23 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017333333 | CMS |
| Boehringer Ingelheim International GmbH | $50.00 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017334841 | CMS |
| Novo Nordisk Inc | $32.27 | 05/12/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001978001 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,200.00 | 1 |
| PY2025 | Principal investigator | $6,407,903.58 | 738 |
| PY2024 | Recipient | $12,299.41 | 13 |
| PY2024 | Principal investigator | $7,058,469.69 | 390 |
| PY2023 | Recipient | $3,980.00 | 2 |
| PY2023 | Principal investigator | $7,125,617.33 | 899 |
| PY2022 | Recipient | $9,082.00 | 12 |
| PY2022 | Principal investigator | $6,929,547.49 | 979 |
| PY2021 | Recipient | $14,312.20 | 61 |
| PY2021 | Principal investigator | $9,361,495.59 | 2,459 |
| PY2020 | Recipient | $233.41 | 1 |
| PY2020 | Principal investigator | $5,812,787.31 | 750 |
| PY2019 | Principal investigator | $4,820,055.08 | 826 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
751 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,820.16 | 12/31/2020 | Non-covered Recipient Entity Pmg Research Inc | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736737225 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $73.02 | 12/31/2020 | Non-covered Recipient Entity Pmg Research Of Wilmington | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736742211 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $164.13 | 12/31/2020 | Non-covered Recipient Entity Pmg Research Of Hickory | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736745827 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174155 |
| Principal investigator 1 | PFIZER INC. | $12,842.17 | 12/30/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742892100 |
| Principal investigator 1 | PFIZER INC. | $5,670.94 | 12/29/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742892097 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174153 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $164,332.58 | 12/24/2020 | Non-covered Recipient Entity PMG RESEARCH | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | No dispute reported | 06/30/2026 | 724481879 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,000.00 | 12/23/2020 | Non-covered Recipient Entity PMG Research Inc | Ph IIb dose finding vs placebo in patients with Ob | No dispute reported | 06/30/2026 | 751191663 |
| Principal investigator 1 | Novo Nordisk AS | $596.00 | 12/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177071 |
| Principal investigator 1 | Novo Nordisk AS | $178.00 | 12/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177073 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 742340833 |
| Principal investigator 1 | Novo Nordisk AS | $871.33 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340837 |
| Principal investigator 1 | Novo Nordisk AS | $9,448.04 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340843 |
| Principal investigator 1 | Novo Nordisk AS | $14,538.84 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340849 |
| Principal investigator 1 | Novo Nordisk AS | $800.00 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340851 |
| Principal investigator 1 | Novo Nordisk AS | $14,154.48 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340861 |
| Principal investigator 1 | Novo Nordisk AS | $2,579.40 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340863 |
| Principal investigator 1 | Novo Nordisk AS | $774.25 | 12/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340865 |
| Principal investigator 1 | Novo Nordisk AS | $27.00 | 12/21/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 822169901 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/21/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174159 |
| Principal investigator 1 | PFIZER INC. | $12,809.82 | 12/19/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742892039 |
| Principal investigator 1 | Novo Nordisk AS | $135.00 | 12/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 822171013 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174149 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174151 |
| Principal investigator 1 | PFIZER INC. | $66,884.40 | 12/16/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 742892359 |
| Principal investigator 1 | PFIZER INC. | $15,133.19 | 12/12/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742892043 |
| Principal investigator 1 | Novo Nordisk AS | $400.00 | 12/10/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/10/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724480743 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 12/10/2020 | Non-covered Recipient Entity PMG RESEARCH | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | No dispute reported | 06/30/2026 | 724480745 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174157 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,200.00 | 12/09/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise | No dispute reported | 06/30/2026 | 744045769 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/08/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174147 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $10,500.00 | 12/07/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON, LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older | No dispute reported | 06/30/2026 | 740793303 |
| Principal investigator 1 | PFIZER INC. | $23,061.72 | 12/05/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742892093 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176961 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176963 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176965 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176967 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176969 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176971 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176973 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176975 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176977 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176979 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176981 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176983 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176985 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176987 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176989 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176991 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176993 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176995 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176997 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822176999 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177001 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177003 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177005 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177007 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177009 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177011 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177013 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177015 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177017 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177019 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177021 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177023 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177025 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177027 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177029 |
| Principal investigator 1 | Novo Nordisk AS | $74.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177031 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177033 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177035 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177037 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177039 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177041 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177043 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177045 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177047 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177049 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177051 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177053 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177055 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177057 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177059 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177061 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177063 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177065 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177067 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 822177069 |
| Principal investigator 1 | PFIZER INC. | $508.00 | 12/03/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868325 |
| Principal investigator 1 | PFIZER INC. | $661.50 | 12/03/2020 | Non-covered Recipient Entity PMG Research of Hickory LLC | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742891893 |
| Principal investigator 1 | PFIZER INC. | $66,798.00 | 12/03/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 742892363 |
| Principal investigator 1 | PFIZER INC. | $4,630.50 | 12/03/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742892367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,045.26 | 12/03/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724480277 |
| Principal investigator 1 | Novo Nordisk AS | $41.00 | 12/02/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 822174145 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $800.00 | 12/02/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise | No dispute reported | 06/30/2026 | 744045729 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 12/01/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise | No dispute reported | 06/30/2026 | 744045737 |
| Principal investigator 1 | Novo Nordisk AS | $769.50 | 11/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340841 |
| Principal investigator 1 | Novo Nordisk AS | $5,123.78 | 11/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340845 |
| Principal investigator 1 | PFIZER INC. | $34,118.63 | 11/28/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742913103 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 11/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340853 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 11/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340855 |
| Principal investigator 1 | Novo Nordisk AS | $20,094.41 | 11/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340857 |
| Principal investigator 1 | Novo Nordisk AS | $7,045.46 | 11/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340859 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $51,658.79 | 11/25/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724479713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $897,509.48 | 11/25/2020 | Non-covered Recipient Entity PMG RESEARCH | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | No dispute reported | 06/30/2026 | 724479715 |
| Principal investigator 1 | Novo Nordisk AS | $934.57 | 11/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340835 |
| Principal investigator 1 | Novo Nordisk AS | $130.00 | 11/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340839 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.62 | 11/24/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724479627 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 11/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $518.98 | 11/23/2020 | Non-covered Recipient Entity PMG RESEARCH | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | No dispute reported | 06/30/2026 | 724479471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.76 | 11/23/2020 | Non-covered Recipient Entity PMG RESEARCH | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | No dispute reported | 06/30/2026 | 724479473 |
| Principal investigator 1 | PFIZER INC. | $268,739.95 | 11/21/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 742854603 |
| Principal investigator 1 | PFIZER INC. | $997.51 | 11/21/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868037 |
| Principal investigator 1 | PFIZER INC. | $74,438.76 | 11/21/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742913135 |
| Principal investigator 1 | PFIZER INC. | $15,214.50 | 11/21/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920047 |
| Principal investigator 1 | Novo Nordisk AS | $0.30 | 11/20/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340871 |
| Principal investigator 1 | Novo Nordisk AS | $5.72 | 11/20/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340873 |
| Principal investigator 1 | Novo Nordisk AS | $325.80 | 11/20/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340875 |
| Principal investigator 1 | Novo Nordisk AS | $891.00 | 11/20/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340877 |
| Principal investigator 1 | Novo Nordisk AS | $439.20 | 11/20/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340879 |
| Principal investigator 1 | PFIZER INC. | $4,630.50 | 11/19/2020 | Non-covered Recipient Entity PMG Research of Hickory LLC | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742920367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,560.48 | 11/19/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724479203 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 11/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340739 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340881 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340883 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340885 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340887 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340889 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340891 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340893 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340895 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340897 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340899 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340901 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340903 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340905 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340907 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340909 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340911 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340913 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340915 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340917 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340919 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340921 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340923 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340925 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340927 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340929 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340931 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340933 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340935 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340937 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340939 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340941 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340943 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340945 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340947 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340949 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340951 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340953 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340955 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340957 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340959 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340961 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340963 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340965 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340967 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340969 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340971 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340973 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340975 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340977 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340979 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340981 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340983 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340985 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340987 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340989 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340991 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340993 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340995 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340997 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742340999 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341001 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341003 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341005 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341007 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341009 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341011 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341013 |
| Principal investigator 1 | Novo Nordisk AS | $3.02 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341015 |
| Principal investigator 1 | Novo Nordisk AS | $22.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341017 |
| Principal investigator 1 | Novo Nordisk AS | $8.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341019 |
| Principal investigator 1 | Novo Nordisk AS | $72.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341021 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341023 |
| Principal investigator 1 | Novo Nordisk AS | $39.90 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341025 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341027 |
| Principal investigator 1 | Novo Nordisk AS | $9.74 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341029 |
| Principal investigator 1 | Novo Nordisk AS | $40.00 | 11/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | NN1436-4477 | No dispute reported | 06/30/2026 | 742341031 |
| Principal investigator 1 | PFIZER INC. | $76,590.12 | 11/17/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742912917 |
| Principal investigator 1 | PFIZER INC. | $2,678.00 | 11/16/2020 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742870793 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29,697.99 | 11/16/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724479039 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 11/13/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340743 |
| Principal investigator 1 | PFIZER INC. | $45,777.56 | 11/11/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742913139 |
| Principal investigator 1 | Eli Lilly and Company | $32.56 | 11/09/2020 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | No dispute reported | 06/30/2026 | 728745059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $818.28 | 11/09/2020 | Non-covered Recipient Entity PMG RESEARCH | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | No dispute reported | 06/30/2026 | 724478721 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $19,479.60 | 11/06/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727263 |
| Principal investigator 1 | Novo Nordisk AS | $562.00 | 11/05/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 742340867 |
| Principal investigator 1 | Novo Nordisk AS | $1,182.00 | 11/05/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 742340869 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 11/03/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340741 |
| Principal investigator 1 | PFIZER INC. | $131,102.55 | 10/31/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742913099 |
| Recipient | Eli Lilly and Company | $233.41 | 10/29/2020 | Covered Recipient Physician | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | No dispute reported | 06/30/2026 | 728722147 |
| Principal investigator 1 | Novo Nordisk AS | $9,876.46 | 10/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340761 |
| Principal investigator 1 | Novo Nordisk AS | $1,987.89 | 10/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340765 |
| Principal investigator 1 | Novo Nordisk AS | $187.50 | 10/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340767 |
| Principal investigator 1 | Novo Nordisk AS | $13,360.01 | 10/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340777 |
| Principal investigator 1 | Novo Nordisk AS | $738.13 | 10/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340789 |
| Principal investigator 1 | Novo Nordisk AS | $1,267.52 | 10/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340791 |
| Principal investigator 1 | Novo Nordisk AS | $1,187.50 | 10/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340803 |
| Principal investigator 1 | PFIZER INC. | $7,276.50 | 10/29/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920229 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340637 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340633 |
| Principal investigator 1 | Novo Nordisk AS | $130.00 | 10/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $18,230.45 | 10/27/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724478007 |
| Principal investigator 1 | PFIZER INC. | $96,175.67 | 10/23/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742912923 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340727 |
| Principal investigator 1 | PFIZER INC. | $37,725.40 | 10/22/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920371 |
| Principal investigator 1 | PFIZER INC. | $1,985.38 | 10/22/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $397,108.65 | 10/22/2020 | Non-covered Recipient Entity PMG RESEARCH | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | No dispute reported | 06/30/2026 | 724477797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.62 | 10/22/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724477885 |
| Principal investigator 1 | PFIZER INC. | $92,690.35 | 10/20/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742913095 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/19/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340635 |
| Principal investigator 1 | PFIZER INC. | $1,773.90 | 10/17/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868039 |
| Principal investigator 1 | PFIZER INC. | $10,584.00 | 10/17/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920551 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/16/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340725 |
| Principal investigator 1 | PFIZER INC. | $156,267.38 | 10/10/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742913049 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,778.00 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727265 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340611 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340613 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340615 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340617 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340619 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340621 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340623 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340625 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340627 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340629 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340631 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340639 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340641 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340643 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340645 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340647 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340649 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340651 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340653 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340655 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340657 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340659 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340661 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340663 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340665 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340667 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340669 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340671 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340673 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340675 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340677 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340679 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340681 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340683 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340685 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340687 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340689 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340691 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340693 |
| Principal investigator 1 | Novo Nordisk AS | $749.75 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340695 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340697 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340699 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340701 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340703 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340705 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340707 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340709 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340711 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340713 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340715 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340717 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340719 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340721 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 10/09/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 10/08/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724476635 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,000.00 | 10/08/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724476639 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340829 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340831 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 10/02/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340827 |
| Principal investigator 1 | PFIZER INC. | $25,361.20 | 10/02/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868043 |
| Principal investigator 1 | PFIZER INC. | $191,330.42 | 10/02/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742912921 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,756.40 | 10/01/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734915555 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,878.20 | 10/01/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734923357 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,878.20 | 10/01/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523551 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,756.40 | 10/01/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523559 |
| Principal investigator 1 | PFIZER INC. | $5,953.50 | 10/01/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920465 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 10/01/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920557 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340807 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340809 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340805 |
| Principal investigator 1 | PFIZER INC. | $204,892.68 | 09/26/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742943905 |
| Principal investigator 1 | Novo Nordisk AS | $7,877.33 | 09/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340775 |
| Principal investigator 1 | Novo Nordisk AS | $11,408.14 | 09/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340783 |
| Principal investigator 1 | Novo Nordisk AS | $279.30 | 09/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340785 |
| Principal investigator 1 | Novo Nordisk AS | $200.00 | 09/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340787 |
| Principal investigator 1 | Novo Nordisk AS | $2,698.01 | 09/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340801 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340817 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340811 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 09/23/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045645 |
| Principal investigator 1 | Novo Nordisk AS | $2,536.79 | 09/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340755 |
| Principal investigator 1 | Novo Nordisk AS | $260.00 | 09/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340757 |
| Principal investigator 1 | Novo Nordisk AS | $1,245.69 | 09/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340763 |
| Principal investigator 1 | Novo Nordisk AS | $644.85 | 09/22/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340797 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/21/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340819 |
| Principal investigator 1 | PFIZER INC. | $13,058.52 | 09/19/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742920051 |
| Principal investigator 1 | PFIZER INC. | $142,759.06 | 09/19/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742943841 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,839.00 | 09/18/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727233 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340813 |
| Principal investigator 1 | Novo Nordisk AS | $41.06 | 09/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,759.95 | 09/17/2020 | Non-covered Recipient Entity PMG RESEARCH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 | No dispute reported | 06/30/2026 | 724475111 |
| Principal investigator 1 | PFIZER INC. | $197,634.64 | 09/12/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742943847 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 09/11/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340823 |
| Principal investigator 1 | PFIZER INC. | $161,575.47 | 09/10/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742944167 |
| Principal investigator 1 | PFIZER INC. | $4,759.47 | 09/09/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 742855521 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 09/04/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045621 |
| Principal investigator 1 | PFIZER INC. | $3,172.98 | 09/03/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 742855597 |
| Principal investigator 1 | Novo Nordisk AS | $48,702.77 | 09/01/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340749 |
| Principal investigator 1 | Novo Nordisk AS | $0.32 | 09/01/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340821 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 09/01/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340825 |
| Principal investigator 1 | PFIZER INC. | $1,586.49 | 08/31/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 742855523 |
| Principal investigator 1 | PFIZER INC. | $85,273.53 | 08/29/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742943907 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340745 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340747 |
| Principal investigator 1 | Novo Nordisk AS | $9,340.60 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340751 |
| Principal investigator 1 | Novo Nordisk AS | $520.00 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340753 |
| Principal investigator 1 | Novo Nordisk AS | $12,345.29 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340773 |
| Principal investigator 1 | Novo Nordisk AS | $10,919.87 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340779 |
| Principal investigator 1 | Novo Nordisk AS | $200.00 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340781 |
| Principal investigator 1 | Novo Nordisk AS | $2,901.82 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340793 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340795 |
| Principal investigator 1 | Novo Nordisk AS | $774.25 | 08/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340799 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340597 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.62 | 08/26/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724474151 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340589 |
| Principal investigator 1 | Novo Nordisk AS | $2,149.37 | 08/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340769 |
| Principal investigator 1 | Novo Nordisk AS | $1,050.94 | 08/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340771 |
| Principal investigator 1 | PFIZER INC. | $96,977.74 | 08/22/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742944165 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 08/21/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340607 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/21/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340609 |
| Principal investigator 1 | Astellas Pharma Global Development | $8,349.00 | 08/20/2020 | Covered Recipient Teaching Hospital VANDERBILT UNIVERSITY MEDICAL CENTER | PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) | No dispute reported | 06/30/2026 | 721320947 |
| Principal investigator 1 | PFIZER INC. | $22,491.00 | 08/19/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742944069 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,416.00 | 08/17/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients | No dispute reported | 06/30/2026 | 744017460 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 08/14/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340601 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/14/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340603 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/14/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $225.00 | 08/13/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724473323 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $7,359.20 | 08/12/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727225 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,953.25 | 08/12/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045637 |
| Principal investigator 1 | PFIZER INC. | $1,339.00 | 08/11/2020 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868321 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $2,050.00 | 08/10/2020 | Non-covered Recipient Entity PMG RESEARCH INC | EFC-14837 | No dispute reported | 06/30/2026 | 752054539 |
| Principal investigator 1 | Novo Nordisk AS | $142.89 | 08/05/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340593 |
| Principal investigator 1 | Novo Nordisk AS | $73.37 | 08/05/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340595 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340585 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340587 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 08/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340591 |
| Principal investigator 1 | PFIZER INC. | $18,160.50 | 08/01/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742944163 |
| Principal investigator 1 | Novo Nordisk AS | $90.93 | 07/31/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340733 |
| Principal investigator 1 | Novo Nordisk AS | $46.69 | 07/31/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340735 |
| Principal investigator 1 | Novo Nordisk AS | $2,375.00 | 07/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340499 |
| Principal investigator 1 | Novo Nordisk AS | $200.00 | 07/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340501 |
| Principal investigator 1 | Novo Nordisk AS | $15,606.82 | 07/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340523 |
| Principal investigator 1 | Novo Nordisk AS | $8,246.30 | 07/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340533 |
| Principal investigator 1 | Novo Nordisk AS | $750.00 | 07/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340535 |
| Principal investigator 1 | PFIZER INC. | $8,000.00 | 07/30/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,112.18 | 07/29/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724472403 |
| Principal investigator 1 | Novo Nordisk AS | $2,425.49 | 07/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340505 |
| Principal investigator 1 | Novo Nordisk AS | $200.00 | 07/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340507 |
| Principal investigator 1 | Novo Nordisk AS | $3,676.65 | 07/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340513 |
| Principal investigator 1 | Novo Nordisk AS | $130.00 | 07/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340515 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 07/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340517 |
| Principal investigator 1 | Novo Nordisk AS | $90.93 | 07/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340729 |
| Principal investigator 1 | Novo Nordisk AS | $46.69 | 07/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $34,016.88 | 07/27/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724471799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.62 | 07/23/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724471339 |
| Principal investigator 1 | PFIZER INC. | $31,164.75 | 07/17/2020 | Non-covered Recipient Entity PMG Research of Hickory LLC | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742944113 |
| Principal investigator 1 | PFIZER INC. | $19,385.86 | 07/17/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742944119 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $38.23 | 07/15/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727151 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4,490.80 | 07/15/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727153 |
| Principal investigator 1 | PFIZER INC. | $669.50 | 07/13/2020 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868155 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $803.25 | 07/10/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045631 |
| Principal investigator 1 | PFIZER INC. | $10,500.00 | 07/04/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742943845 |
| Principal investigator 1 | PFIZER INC. | $10,054.72 | 07/02/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742944117 |
| Principal investigator 1 | PFIZER INC. | $669.50 | 06/29/2020 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868153 |
| Principal investigator 1 | Novo Nordisk AS | $1,786.00 | 06/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340509 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 06/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340511 |
| Principal investigator 1 | Novo Nordisk AS | $200.00 | 06/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340531 |
| Principal investigator 1 | PFIZER INC. | $3,606.75 | 06/25/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742935110 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340539 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340541 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340543 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340545 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340547 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340549 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340551 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340553 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340555 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340557 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340559 |
| Principal investigator 1 | Novo Nordisk AS | $900.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340561 |
| Principal investigator 1 | Novo Nordisk AS | $64.16 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340563 |
| Principal investigator 1 | Novo Nordisk AS | $36.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340565 |
| Principal investigator 1 | Novo Nordisk AS | $10.60 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340567 |
| Principal investigator 1 | Novo Nordisk AS | $2.24 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340569 |
| Principal investigator 1 | Novo Nordisk AS | $19.60 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340571 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340573 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340575 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340577 |
| Principal investigator 1 | Novo Nordisk AS | $72.00 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $18,589.41 | 06/24/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724468589 |
| Principal investigator 1 | Novo Nordisk AS | $1,632.82 | 06/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340497 |
| Principal investigator 1 | Novo Nordisk AS | $2,247.37 | 06/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340503 |
| Principal investigator 1 | Novo Nordisk AS | $529.87 | 06/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340519 |
| Principal investigator 1 | Novo Nordisk AS | $14,279.73 | 06/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340521 |
| Principal investigator 1 | Novo Nordisk AS | $10,444.00 | 06/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340529 |
| Principal investigator 1 | Novo Nordisk AS | $912.38 | 06/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340537 |
| Principal investigator 1 | PFIZER INC. | $34,883.74 | 06/16/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742944067 |
| Principal investigator 1 | PFIZER INC. | $2,678.00 | 06/15/2020 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 742868149 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,050.00 | 06/10/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045685 |
| Principal investigator 1 | Novo Nordisk AS | $2.99 | 06/08/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340581 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 06/08/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340583 |
| Principal investigator 1 | Novo Nordisk AS | $1,250.00 | 06/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | INS-4391 | No dispute reported | 06/30/2026 | 742340525 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 06/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | INS-4391 | No dispute reported | 06/30/2026 | 742340527 |
| Principal investigator 1 | PFIZER INC. | $28,934.01 | 06/04/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742941499 |
| Principal investigator 1 | PFIZER INC. | $28,512.89 | 06/04/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 742941501 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,034.00 | 06/01/2020 | Non-covered Recipient Entity Pmg Research Of Hickory | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736750415 |
| Principal investigator 1 | Novo Nordisk AS | $1,774.42 | 05/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340153 |
| Principal investigator 1 | Novo Nordisk AS | $466.29 | 05/29/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340155 |
| Principal investigator 1 | PFIZER INC. | $33,998.98 | 05/29/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742965095 |
| Principal investigator 1 | Novo Nordisk AS | $9,189.05 | 05/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340187 |
| Principal investigator 1 | Novo Nordisk AS | $400.00 | 05/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340189 |
| Principal investigator 1 | Novo Nordisk AS | $9,208.26 | 05/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340209 |
| Principal investigator 1 | Novo Nordisk AS | $703.29 | 05/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340219 |
| Principal investigator 1 | Novo Nordisk AS | $3,491.83 | 05/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340229 |
| Principal investigator 1 | Novo Nordisk AS | $17,907.59 | 05/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340243 |
| Principal investigator 1 | Novo Nordisk AS | $187.50 | 05/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340245 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,350.00 | 05/28/2020 | Non-covered Recipient Entity Pmg Research,Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc | No dispute reported | 06/30/2026 | 744017703 |
| Principal investigator 1 | Novo Nordisk AS | $144.09 | 05/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340371 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,797.00 | 05/27/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724465467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,996.70 | 05/27/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724465471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,206.30 | 05/27/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724465479 |
| Principal investigator 1 | Novo Nordisk AS | $1,589.62 | 05/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340169 |
| Principal investigator 1 | Novo Nordisk AS | $3,648.41 | 05/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340199 |
| Principal investigator 1 | PFIZER INC. | $10,045.90 | 05/21/2020 | Non-covered Recipient Entity PMG Research of Hickory LLC | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742965099 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,380.55 | 05/21/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724464389 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,458.90 | 05/20/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734904697 |
| Principal investigator 1 | PFIZER INC. | $13,579.72 | 05/15/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742934803 |
| Principal investigator 1 | PFIZER INC. | $23,944.26 | 05/15/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742965171 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $137.50 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727155 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16.50 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727157 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $168.00 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727159 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $19.00 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727161 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3.50 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727165 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $34.00 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727167 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $35.50 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727169 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $47.50 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727171 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5.00 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727173 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $6.50 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727175 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $605.00 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727189 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,320.00 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727191 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $297.00 | 05/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727193 |
| Principal investigator 1 | PFIZER INC. | $33,883.47 | 05/08/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742934147 |
| Principal investigator 1 | Novo Nordisk AS | $1.99 | 05/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340373 |
| Principal investigator 1 | Novo Nordisk AS | $2.99 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340375 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340377 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340379 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340381 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340383 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340385 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340387 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340389 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340391 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340393 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340395 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340397 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340399 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340401 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340403 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340405 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340407 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340409 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340411 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340413 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340415 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340417 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340419 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340421 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340423 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340425 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340427 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340429 |
| Principal investigator 1 | Novo Nordisk AS | $202.50 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340431 |
| Principal investigator 1 | Novo Nordisk AS | $417.50 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340433 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340435 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340437 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340439 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340441 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340443 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340445 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340447 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340449 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340451 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340453 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340455 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340457 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340459 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340461 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340463 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340465 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340467 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340469 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340471 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340473 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340475 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340477 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340479 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340481 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340483 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340485 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340487 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340489 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340491 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340493 |
| Principal investigator 1 | Novo Nordisk AS | $17.40 | 05/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340495 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,350.00 | 05/04/2020 | Non-covered Recipient Entity Pmg Research Of Wilmington | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc | No dispute reported | 06/30/2026 | 744017695 |
| Principal investigator 1 | PFIZER INC. | $19,345.16 | 05/01/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742964927 |
| Principal investigator 1 | Novo Nordisk AS | $10,964.31 | 04/30/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340185 |
| Principal investigator 1 | PFIZER INC. | $20,103.75 | 04/30/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 742937433 |
| Principal investigator 1 | PFIZER INC. | $8,983.92 | 04/30/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742965227 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,609.75 | 04/29/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045679 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 04/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340361 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 04/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340363 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 04/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340365 |
| Principal investigator 1 | Novo Nordisk AS | $5,291.95 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340149 |
| Principal investigator 1 | Novo Nordisk AS | $130.00 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340151 |
| Principal investigator 1 | Novo Nordisk AS | $5,664.67 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340167 |
| Principal investigator 1 | Novo Nordisk AS | $14,947.97 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340197 |
| Principal investigator 1 | Novo Nordisk AS | $2,731.29 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340207 |
| Principal investigator 1 | Novo Nordisk AS | $1,530.39 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340217 |
| Principal investigator 1 | Novo Nordisk AS | $14,720.53 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340225 |
| Principal investigator 1 | Novo Nordisk AS | $5,100.00 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340227 |
| Principal investigator 1 | Novo Nordisk AS | $13,404.56 | 04/23/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.31 | 04/22/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724461643 |
| Principal investigator 1 | PFIZER INC. | $38,762.66 | 04/21/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742965231 |
| Principal investigator 1 | PFIZER INC. | $2,069.55 | 04/21/2020 | Non-covered Recipient Entity PMG Research of Hickory LLC | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742965233 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $460.00 | 04/20/2020 | Non-covered Recipient Entity Pmg Research Of Wilmington | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736739283 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $250.00 | 04/17/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727145 |
| Principal investigator 1 | Novo Nordisk AS | $808.32 | 04/16/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN8022-4272 | No dispute reported | 06/30/2026 | 742340171 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $17,862.40 | 04/15/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727149 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,159.20 | 04/08/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734901981 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $297.00 | 04/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727163 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $605.00 | 04/08/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727195 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,705.27 | 04/08/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724460151 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27,027.00 | 04/08/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724460161 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340339 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340341 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340343 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340345 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340347 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340349 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340351 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340353 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340355 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340357 |
| Principal investigator 1 | Novo Nordisk AS | $360.00 | 04/07/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340359 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,378.80 | 04/01/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734900635 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,398.50 | 04/01/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734900869 |
| Principal investigator 1 | PFIZER INC. | $513.00 | 04/01/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742934139 |
| Principal investigator 1 | Novo Nordisk AS | $2,582.34 | 03/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340165 |
| Principal investigator 1 | Novo Nordisk AS | $14,245.29 | 03/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340205 |
| Principal investigator 1 | Novo Nordisk AS | $2,127.25 | 03/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340221 |
| Principal investigator 1 | Novo Nordisk AS | $372.75 | 03/26/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340223 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,398.60 | 03/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753908543 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,159.20 | 03/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753908611 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,539.00 | 03/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753908863 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,458.90 | 03/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753910163 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,539.00 | 03/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523549 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,159.20 | 03/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523553 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,253.25 | 03/25/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045513 |
| Principal investigator 1 | Novo Nordisk AS | $2,217.46 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340143 |
| Principal investigator 1 | Novo Nordisk AS | $600.00 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340145 |
| Principal investigator 1 | Novo Nordisk AS | $5,572.51 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340147 |
| Principal investigator 1 | Novo Nordisk AS | $20,353.62 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340181 |
| Principal investigator 1 | Novo Nordisk AS | $1,200.00 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340183 |
| Principal investigator 1 | Novo Nordisk AS | $6,421.36 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340195 |
| Principal investigator 1 | Novo Nordisk AS | $1,487.64 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340215 |
| Principal investigator 1 | Novo Nordisk AS | $29,624.70 | 03/24/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340239 |
| Principal investigator 1 | PFIZER INC. | $18,435.94 | 03/19/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742965173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,560.48 | 03/19/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724458231 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,775.40 | 03/18/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753908605 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,458.90 | 03/18/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753909545 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,775.40 | 03/18/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523557 |
| Principal investigator 1 | PFIZER INC. | $327.04 | 03/18/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742937965 |
| Principal investigator 1 | PFIZER INC. | $2,069.55 | 03/18/2020 | Non-covered Recipient Entity PMG Research of Hickory LLC | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 742965175 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15,627.00 | 03/16/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727109 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/16/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340367 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $255.00 | 03/13/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045507 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $675.00 | 03/12/2020 | Non-covered Recipient Entity PMG RESEARCH INC | EFC-14868 | No dispute reported | 06/30/2026 | 752054549 |
| Principal investigator 1 | PFIZER INC. | $4,356.75 | 03/12/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742937703 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 03/12/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742962421 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 03/12/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742965093 |
| Principal investigator 1 | PFIZER INC. | $375.00 | 03/12/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742965391 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,284.00 | 03/12/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc | No dispute reported | 06/30/2026 | 744017633 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,350.00 | 03/12/2020 | Non-covered Recipient Entity Pmg Research Of Wilmington | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc | No dispute reported | 06/30/2026 | 744017639 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,224.37 | 03/11/2020 | Non-covered Recipient Entity Pmg Research Of Wilmington | Phase II study of BI456906 in Patients with T2DM O | No dispute reported | 06/30/2026 | 751190693 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,458.90 | 03/11/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753909661 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,458.90 | 03/11/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523563 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,500.00 | 03/09/2020 | Non-covered Recipient Entity PMG Research Inc | Phase II study of BI456906 in Patients with T2DM O | No dispute reported | 06/30/2026 | 751190717 |
| Principal investigator 1 | Novo Nordisk AS | $7.98 | 03/06/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340337 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $85.00 | 03/06/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045339 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $700.00 | 03/06/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38,469.56 | 03/05/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724456883 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,600.00 | 03/05/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients | No dispute reported | 06/30/2026 | 744017667 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,378.80 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH INC | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 753908115 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,378.80 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523555 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340305 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340307 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340309 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340311 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340313 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340315 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340317 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340319 |
| Principal investigator 1 | Novo Nordisk AS | $24.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340321 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340323 |
| Principal investigator 1 | Novo Nordisk AS | $74.97 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340325 |
| Principal investigator 1 | Novo Nordisk AS | $13.50 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340327 |
| Principal investigator 1 | Novo Nordisk AS | $90.00 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340329 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340331 |
| Principal investigator 1 | Novo Nordisk AS | $13.50 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340333 |
| Principal investigator 1 | Novo Nordisk AS | $54.00 | 03/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 742340335 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $225.00 | 03/02/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045337 |
| Principal investigator 1 | PFIZER INC. | $3,606.75 | 02/28/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 742937055 |
| Principal investigator 1 | PFIZER INC. | $4,911.80 | 02/28/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742979565 |
| Principal investigator 1 | Novo Nordisk AS | $14,083.39 | 02/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340175 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 02/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340177 |
| Principal investigator 1 | Novo Nordisk AS | $187.50 | 02/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340179 |
| Principal investigator 1 | Novo Nordisk AS | $29,749.63 | 02/27/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340203 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,403.25 | 02/26/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045323 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,500.00 | 02/26/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045329 |
| Principal investigator 1 | Novo Nordisk AS | $5,978.78 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340139 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340141 |
| Principal investigator 1 | Novo Nordisk AS | $3,271.80 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340159 |
| Principal investigator 1 | Novo Nordisk AS | $187.50 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340161 |
| Principal investigator 1 | Novo Nordisk AS | $940.00 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340163 |
| Principal investigator 1 | Novo Nordisk AS | $13,051.21 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340193 |
| Principal investigator 1 | Novo Nordisk AS | $4,254.81 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340213 |
| Principal investigator 1 | Novo Nordisk AS | $23,528.66 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340233 |
| Principal investigator 1 | Novo Nordisk AS | $2,000.00 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340235 |
| Principal investigator 1 | Novo Nordisk AS | $375.00 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340237 |
| Principal investigator 1 | PFIZER INC. | $459.00 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 742979095 |
| Principal investigator 1 | PFIZER INC. | $532.24 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 742980037 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,468.99 | 02/25/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724456045 |
| Principal investigator 1 | PFIZER INC. | $1,635.20 | 02/21/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742937375 |
| Principal investigator 1 | PFIZER INC. | $11,683.56 | 02/21/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742979527 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,496.50 | 02/19/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734927433 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,496.50 | 02/19/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523565 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 02/19/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340301 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/19/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340303 |
| Principal investigator 1 | PFIZER INC. | $480.94 | 02/19/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742980032 |
| Principal investigator 1 | Novo Nordisk AS | $33.15 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340251 |
| Principal investigator 1 | Novo Nordisk AS | $174.75 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340253 |
| Principal investigator 1 | Novo Nordisk AS | $450.00 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340255 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340257 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340259 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340261 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340263 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340265 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340267 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340269 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340271 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340273 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340275 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340277 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340279 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340281 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340283 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340285 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340287 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340289 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340291 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340293 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340295 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340297 |
| Principal investigator 1 | Novo Nordisk AS | $73.97 | 02/18/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340299 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/12/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340249 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $2,050.00 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH INC | EFC-14838 | No dispute reported | 06/30/2026 | 752054541 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,320.00 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727117 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16.50 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727119 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $168.00 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727121 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $19.00 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727123 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3.50 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727125 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $34.00 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727127 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $47.50 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727129 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $6.50 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727131 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $605.00 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727133 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $137.50 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727139 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5.00 | 02/10/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727143 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 02/04/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340247 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $200.00 | 02/03/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727115 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,103.25 | 02/03/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045316 |
| Principal investigator 1 | PFIZER INC. | $2,632.89 | 02/01/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742937051 |
| Principal investigator 1 | PFIZER INC. | $16,749.06 | 02/01/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742979531 |
| Principal investigator 1 | PFIZER INC. | $1,635.20 | 01/31/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742937333 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 01/30/2020 | Non-covered Recipient Entity PMG Research of Charlotte | PHASE III LOT CONSISTENCY TRIAL | No dispute reported | 06/30/2026 | 742979987 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5,302.00 | 01/29/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727111 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340135 |
| Principal investigator 1 | Novo Nordisk AS | $1,655.37 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 742340137 |
| Principal investigator 1 | Novo Nordisk AS | $4,786.22 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4374 | No dispute reported | 06/30/2026 | 742340157 |
| Principal investigator 1 | Novo Nordisk AS | $8,718.24 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340173 |
| Principal investigator 1 | Novo Nordisk AS | $14,078.17 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 742340191 |
| Principal investigator 1 | Novo Nordisk AS | $17,701.05 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 742340201 |
| Principal investigator 1 | Novo Nordisk AS | $5,415.31 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 742340211 |
| Principal investigator 1 | Novo Nordisk AS | $26,839.11 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 742340231 |
| Principal investigator 1 | PFIZER INC. | $19,065.45 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 742979091 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,549.91 | 01/28/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 724452913 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $68,167.00 | 01/24/2020 | Non-covered Recipient Entity Pmg Research Inc | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | No dispute reported | 06/30/2026 | 736741527 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $847.00 | 01/23/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc | No dispute reported | 06/30/2026 | 744017687 |
| Principal investigator 1 | PFIZER INC. | $1,308.16 | 01/22/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742937335 |
| Principal investigator 1 | PFIZER INC. | $3,126.11 | 01/22/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742979963 |
| Principal investigator 1 | Flexion Therapeutics, Inc. | $750.54 | 01/20/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis | No dispute reported | 06/30/2026 | 752446097 |
| Principal investigator 1 | PFIZER INC. | $240.47 | 01/17/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742979087 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,693.74 | 01/17/2020 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 724451509 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $255.00 | 01/17/2020 | Non-covered Recipient Entity Pmg Research,Incorporation | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | No dispute reported | 06/30/2026 | 744045309 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $17,337.00 | 01/16/2020 | Non-covered Recipient Entity PMG RESEARCH INC | EFC-15294 | No dispute reported | 06/30/2026 | 752054551 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5,900.00 | 01/13/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727113 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 01/10/2020 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 742340369 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $20.00 | 01/09/2020 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 740727141 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,998.00 | 01/08/2020 | Non-covered Recipient Entity PMG RESEARCH | RSV OA=ADJ-002 | No dispute reported | 06/30/2026 | 734903095 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,998.00 | 01/08/2020 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN | No dispute reported | 06/30/2026 | 965523561 |
| Principal investigator 1 | PFIZER INC. | $3,270.40 | 01/08/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | No dispute reported | 06/30/2026 | 742935180 |
| Principal investigator 1 | PFIZER INC. | $29,837.50 | 01/08/2020 | Non-covered Recipient Entity PMG Research of Wilmington LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 742979995 |